FDA Updates Container Closure System Guidance 2026: What Drug & Biologic Manufacturers Need To Know

What the New FDA Guidance Means for Pharmaceutical Packaging, CCS Quality, Safety, CMC Documentation and Lifecycle Management

The U.S. Food and Drug Administration (FDA) has updated its guidance for industry on Container Closure Systems (CCS) for Packaging Human Drugs and Biologics, replacing the previous guidance issued in May 1999.

After 27 years, the update reflects major advances in pharmaceutical packaging, including new materials, container designs, analytical technologies, combination products, biologics and approaches for evaluating packaging quality and safety.

The guidance applies to New Drug Applications (NDAs), Biologics License Applications (BLAs), amendments and supplements, as well as applicable combination products.

For pharmaceutical and biotechnology companies, this is an important opportunity to reassess how container and closure systems are selected, qualified, tested and documented throughout the product lifecycle.

Why Container Closure Systems Matter

A container closure system is an important part of a drug product's overall quality strategy. Packaging must protect the product from environmental and physical factors while maintaining its quality, safety, identity, strength and purity throughout its intended shelf life.

Depending on the product, CCS’ performance may need to be addressed:

• Moisture 
• Oxygen 
• Light 
• Microbial contamination 
• Physical damage 
• Chemical interaction 
• Product loss 
• Temperature and distribution conditions 

Packaging can also interact with drug products. Materials may potentially contribute extractables and leachables, adsorption, absorption or other interactions that could affect product quality or patient safety.

Therefore, CCS evaluation should be integrated with CMC, formulation, stability, manufacturing and quality programs, rather than treated simply as a packaging activity.

Who Should Pay Attention to Updated Guidance?

The updated recommendations are relevant to companies developing or maintaining human drug and biological products.

Companies should determine how the guidance affects their specific product based on dosage form, route of administration, packaging configuration, product sensitivity and regulatory status.

From the 1999 Approach to Modern Packaging Science

The previous guidance was developed when pharmaceutical packaging technologies and analytical capabilities were considerably different.

Since 1999, the industry has seen substantial development in:

• Advanced polymers 
• Elastomers 
• Coatings and barrier materials 
• Prefilled syringes 
• Cartridges 
• Autoinjectors 
• Biologic packaging 
• Extractables and leachables testing 
• Container closure integrity testing 
• Advanced analytical techniques 
• Cold-chain distribution 
• Drug-device combination systems

The updated guidance reflects the need for a more modern, science-based evaluation of packaging systems.

For companies, this means that historical packaging information may need to be reviewed to determine whether it remains appropriate for today's products and technologies.

What Is a Container Closure System?

A CCS includes the components that together contain and protect a drug or biological product.

Examples include:

• Bottles 
• Vials 
• Ampoules 
• Syringes 
• Cartridges 
• Stoppers 
• Plungers 
• Caps 
• Seals 
• Liners 
• Tubes 
• Other primary packaging components 

The complete system should be evaluated because individual components can interact with one another and with the drug product.

The assessment should consider the intended configuration, manufacturing process, storage conditions, distribution environment and patient-use conditions.

Core Quality and Safety Considerations

A suitable CCS should demonstrate that it can perform its intended function throughout the product lifecycle.

Key areas include:

1. Product Protection

The system should protect the drug from environmental factors that could compromise quality.

2. Compatibility

Packaging materials should not adversely affect the drug product or introduce unacceptable substances.

3. Stability

The CCS should support the proposed shelf life and storage conditions.

4. Container Closure Integrity

Where appropriate, the system should maintain its protective barrier and prevent contamination or unacceptable product loss.

5. Material Safety

Packaging materials should be appropriately characterized and suitable for pharmaceutical use.

6. Functional Performance

Components should perform reliably during manufacturing, transportation, storage and intended use.

Extractables and Leachables

Extractables and leachables (E&L) remain an important consideration in modern CCS assessment.

Extractables are substances that may be released from packaging materials under exaggerated laboratory conditions, while leachables are substances that migrate into the drug product under actual storage or use conditions.

An appropriate assessment may be considered:

• Packaging composition 
• Extraction conditions 
• Potential leachables 
• Contact duration 
• Temperature 
• Formulation characteristics 
• Route of administration 
• Toxicological significance 

The level of assessment should be scientifically justified based on the product and CCS.

This is especially important for sensitive formulations, long shelf-life products, injectable products and systems containing multiple polymeric or elastomeric components.

Container Closure Integrity

Container Closure Integrity (CCI) can be critical for products that require protection from microbial contamination or environmental exposure.

CCI considerations may be particularly important for:

• Sterile products 
• Injectables 
• Ophthalmic products 
• Biologics 
• Moisture-sensitive products 
• Oxygen-sensitive products 

Companies should select suitable integrity-testing approaches based on CCS design and product characteristics.

CCI should also be considered alongside manufacturing processes, sterilization, storage and transportation conditions.

Packaging Materials and Supplier Controls

Modern CCS assessment should address the materials used in each component.

Common materials include:

• Glass 
• Plastics 
• Elastomers 
• Metals 
• Coatings 
• Adhesives 
• Laminates 

Companies should maintain appropriate information on material identity, composition, specifications, manufacturing processes and functional characteristics.

Supplier qualifications are equally important. Changes in raw materials, manufacturing sites, processing conditions or component specifications can potentially affect CCS performance.

A robust supplier-control program should therefore form part of the overall packaging quality strategy.

CMC Documentation

CCS information is an important component of the Chemistry, Manufacturing and Controls (CMC) package.

Packaging information should remain consistent with:

• Drug-product composition 
• Manufacturing process 
• Stability data 
• Specifications 
• Storage conditions 
• Product description 
• Application commitments 

Companies should avoid discrepancies between packaging specifications, stability protocols, manufacturing documents and regulatory submissions.

A clearly organized CCS section can also make regulatory review more efficient by demonstrating how the packaging system supports product quality and safety.

Storage, Transportation and Distribution

Packaging suitability should be evaluated throughout the product's distribution lifecycle not only at the manufacturing site.

Companies should consider:

Manufacturing → Filling → Storage → Transportation → Warehousing → Distribution → Patient Use

Potential factors include:

• Temperature 
• Humidity 
• Vibration 
• Mechanical stress 
• Light exposure 
• Transportation duration 
• Temperature excursions 
• Handling conditions 

This is particularly important for biologics and other temperature-sensitive products.

Packaging qualification should therefore be connected to stability programs and realistic distribution conditions.

Special Considerations for Biologics and Combination Products

Biological products can be especially sensitive to packaging interactions.

Potential concerns include:

• Adsorption 
• Surface interaction 
• Oxygen sensitivity 
• Temperature sensitivity 
• Silicone or lubricant-related effects 
• Extractables and leachables 
• Agitation during transportation

Prefilled syringes, cartridges and autoinjectors may require additional assessment because packaging can also function as part of the delivery system.

For combination products, companies should evaluate the relationship between the container, drug or biologic and delivery device as an integrated system.

2026 CCS Compliance Readiness Checklist

Business Benefits of Strong CCS Management

Existing Products and Packaging Changes

The update is also relevant to companies managing approved products.

Packaging changes may involve:

• Container material 
• Closure material 
• Component supplier 
• Component dimensions 
• Packaging configuration 
• Coating 
• Sterilization 
• Manufacturing site 
• Manufacturing process 

Each change should be evaluated for potential impact on:

• Product quality 
• Stability 
• Compatibility 
• Sterility 
• CCI 
• Regulatory commitments 

Companies should avoid treating a packaging change as purely operational without assessing its regulatory and quality implications.

Practical FDA CCS Compliance Roadmap

A practical implementation approach can include:

1. Identify affected NDAs, BLAs and related applications. 
2. Inventory exists CCS configurations. 
3. Review packaging material specifications. 
4. Evaluate product-packaging compatibility. 
5. Review E&L assessments. 
6. Assess CCI evidence. 
7. Review stability data. 
8. Evaluate storage and distribution conditions. 
9. Confirm supplier controls. 
10. Review CMC documentation. 
11. Assess approved-product packaging changes. 
12. Update internal CCS procedures where appropriate. 

The objective is to create a science-based, lifecycle-focused CCS strategy rather than simply updating regulatory documents.

Common CCS Compliance Challenges

Companies may face:

• Incomplete packaging documentation 
• Insufficient material characterization 
• Weak supplier controls 
• Inadequate compatibility assessment 
• Incomplete E&L studies 
• Insufficient CCI evidence 
• Packaging changes without adequate regulatory assessment 
• Inconsistent CMC and stability documentation 
• Failure to evaluate transportation conditions 
• Outdated packaging specifications 
• Weak lifecycles change control 

Addressing these issues early can reduce regulatory questions and prevent avoidable delays.

Benefits of a Modern CCS Strategy

A robust CCS program can provide:

• Better drug-product protection 
• Stronger patient-safety assurance 
• Improved CMC documentation 
• More reliable stability programs 
• Better packaging selection 
• Stronger supplier oversight 
• More effective change control 
• Reduced regulatory uncertainty 
• Improved lifecycle management 

The FDA update should therefore be viewed as an opportunity to strengthen the connection between packaging science, product quality and regulatory compliance.

Frequently Asked Questions

1. What has FDA updated?

FDA has updated its guidance addressing the quality and safety assessment of container closure systems used for human drugs and biologics.

2. Why was the guidance updated?

The previous guidance was issued in 1999. Advances in packaging technologies, materials, analytical methods, biologics and combination products have created a need for a modernized approach.

3. Does the guidance apply to biologics?

Yes. It applies to relevant human drug and biological product submissions.

4. Does it apply to combination products?

Applicable combination products should consider CCS requirements where packaging interacts with the drug, biologic or delivery system.

5. Are E&L assessments important?

Yes. Extractables and leachables can be important to demonstrate compatibility and safety, depending on the product and packaging system.

6. Is CCI testing required for every product?

The need for CCI evaluation depends on the product, CCS and protection requirements. Sterile and sensitive products may require particular attention.

7. Should existing products be reassessed?

Companies should evaluate existing CCS documentation and determine whether their packaging strategy remains appropriate under the updated recommendations.

8. Does FDA guidance have the force of law?

FDA guidance generally represents the Agency's current thinking and recommendations and does not itself create legally enforceable requirements. Alternative approaches may be acceptable when they satisfy applicable laws and regulations.

Conclusion

The FDA's updated container closure system guidance represents a significant modernization of pharmaceutical packaging expectations after 27 years.

For drug and biologic manufacturers, CCS evaluation now needs to be considered as an integral part of CMC, stability, quality, safety and lifecycle management.

Companies should review their packaging materials, supplier controls, compatibility assessments, E&L strategies, CCI evidence, stability data and regulatory documentation.

The greatest value of the update is not simply in changing packaging documentation. It is in encouraging a more science-based and lifecycle-oriented approach to pharmaceutical packaging.

A well-characterized and appropriately controlled container closure system helps protect product quality, maintain stability and support patient safety from manufacturing through distribution and use.

How Maven Regulatory Solutions Can Help

Maven Regulatory Solutions can support pharmaceutical and biotechnology companies with:

• FDA CCS regulatory assessments 
• CMC documentation review 
• Container closure gap assessments 
• Packaging material evaluation 
• Extractables and leachables strategy 
• Container closure integrity assessment 
• Stability and packaging review 
• Supplier documentation review 
• Packaging change assessments 
• Regulatory submission support 
• Lifecycle management 
• Regulatory intelligence 

Our approach helps companies evaluate packaging systems systematically and align their CCS strategy with current regulatory expectations.